Absci
Absci uses generative AI and an integrated drug creation platform to design and optimize biologic drugs, including antibodies, for pharmaceutical companies and patients. Its technology combines AI-driven de novo design, lead optimization, and wet lab validation to create therapeutics against difficult-to-drug targets, aiming to accelerate the development of better biologics for challenging diseases.
Facts
- HQ
- Vancouver, Wash.
- Sectors
- Biotechnology Research
- Founded
- 2011
- Employees
- 159
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
-
Signed a material agreement Jun 24, 2026
-
Leadership or executive-pay change Mar 6, 2026
-
Signed a material agreement Mar 6, 2026
-
Signed a material agreement Nov 4, 2025
-
Signed a material agreement Jul 25, 2025
-
Leadership or executive-pay change Jul 8, 2025
-
Leadership or executive-pay change Apr 28, 2025
-
Signed a material agreement Feb 28, 2024
-
Leadership or executive-pay change Dec 7, 2023
-
Leadership or executive-pay change Aug 17, 2023
-
Leadership or executive-pay change Aug 14, 2023
-
Signed a material agreement Jun 16, 2023
-
Leadership or executive-pay change Jun 6, 2023
-
Leadership or executive-pay change Nov 2, 2022
-
Leadership or executive-pay change Oct 4, 2022
-
Leadership or executive-pay change Sep 20, 2022
-
Leadership or executive-pay change Jul 14, 2022
-
Leadership or executive-pay change Mar 21, 2022
-
Leadership or executive-pay change Jan 10, 2022
-
Leadership or executive-pay change Aug 24, 2021
-
Filed to go public Jun 30, 2021
People
See all 5-
Sean McClain Founder, CEO & Director
-
Sean McClain CEO and Founder
-
Sean McClain Founder and CEO